J&J's Prezista better than Abbott's Kaletra in fighting HIV

09/19/2007 | Bloomberg

Johnson & Johnson's HIV treatment Prezista reduced the amount of the virus to undetectable levels in 84% of patients, as compared with Abbott Laboratories' Kaletra, which lowered the amount in only 78% of patients, researchers report. However, such findings do not imply that Prezista should be recommended in place of Kaletra as a first-line protease inhibitor, a co-author of the study said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA